Medication info

Janumet M Tablets 50/1000 mg (Sitagliptin Phosphate / Metformin Hydrochloride)

Prescription medicationTabletOralExpired
Ingredient · strength
Sitagliptin Phosphate›62.04mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Samchundang Pharmaceutical Co., Ltd.
Appearance
Red oval film-coated tablet
Packaging
30 tablets/box [(10 tablets/PTP) × 3]
Approval status
Expired

MFDS item code 201503339 · Approved 2015.05.29

This product's status changed to Expired on 2025.05.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this product should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This product is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this product should be based on the patient's current treatment regimen. 1. Patients not currently treated with metformin: For patients with no previous history of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this product 50/500 mg twice daily. The dose may be increased to 1 tablet of this product 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this product (see Precautions for Use, 2. Contraindications). 2. Patients treated with metformin: - The recommended initial dose of this product for patients who do not achieve adequate glycemic control with metformin monotherapy is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's existing metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this product may start at their existing doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this product is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should take into account the patient's blood glucose level and existing dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this product in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This product may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this product because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this product should be discontinued immediately. Patients with hepatic impairment This product should not be administered to patients with impaired liver function due to its metformin component (see Precautions for Use, 2. Contraindications).

Ingredients

Manufacturer
Samchundang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is a treatment for patients with type 2 diabetes that combines sitagliptin and metformin. It helps to more effectively manage blood sugar levels when combined with diet and exercise therapy. Therefore, this medication is very helpful in improving blood sugar levels that are difficult to control solely through diet and exercise. It is used to enhance blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, the dose of this product should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This product is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this product should be based on the patient's current treatment regimen. 1. Patients not currently treated with metformin: For patients with no previous history of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this product 50/500 mg twice daily. The dose may be increased to 1 tablet of this product 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this product (see Precautions for Use, 2. Contraindications). 2. Patients treated with metformin: - The recommended initial dose of this product for patients who do not achieve adequate glycemic control with metformin monotherapy is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's existing metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this product may start at their existing doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this product is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should take into account the patient's blood glucose level and existing dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this product in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This product may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this product because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this product should be discontinued immediately. Patients with hepatic impairment This product should not be administered to patients with impaired liver function due to its metformin component (see Precautions for Use, 2. Contraindications).

Precautions

This medication is used in the treatment of diabetes and contains two ingredients: sitagliptin and metformin. While taking this medication, serious allergic reactions may occur, so if you experience symptoms such as skin rash or difficulty breathing, you must stop taking it immediately and consult a doctor. There is a risk of pancreatitis, which is inflammation of the pancreas; therefore, if abdominal pain, vomiting, or severe abdominal pain occurs, visit a hospital immediately. It may be dangerous to take this medication for patients with significantly impaired kidney function or those with severe infections or dehydration, so they should not take it. Additionally, if you are undergoing radiological examinations using contrast agents, you must temporarily stop taking this medication before and after the tests and restart only after confirming normal kidney function. It is safer for women who are pregnant or breastfeeding to avoid taking this medication. During treatment, symptoms of hypoglycemia may appear, so especially when taking it with other diabetes medications, monitor blood sugar levels frequently and take immediate action if symptoms arise. This medication may cause side effects such as gastrointestinal disorders, diarrhea, nausea, headache, etc., so if symptoms are severe, consult a doctor. Patients with liver or kidney problems have a higher risk of side effects from this medication, so regular blood tests and kidney function tests must be conducted for monitoring. It is important to avoid excessive alcohol consumption, and this medication should be temporarily stopped when undergoing surgery or during severe illness. Additionally, regularly check vitamin B12 levels while taking this medication, and supplementation may be needed if levels are low. The safety and efficacy of this medication have not been sufficiently established in children, so it is advisable not to administer it to children under 18 years of age. Elderly patients may have reduced kidney function, so it is important to periodically check kidney function before and during treatment and adjust the dosage accordingly. In case of overdose, seek medical attention immediately and dialysis treatment may be necessary. Finally, while taking this medication, adhere to the prescribed method and dosage, and do not arbitrarily stop or change the dosage without consulting a doctor.

Side effects

  • hypersensitivity
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • exfoliative skin disease
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
Show 31 more
  • headache
  • nausea
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • peripheral edema
  • hypoglycemia
  • dermatitis
  • anorexia
  • weight loss
  • elevated liver enzymes
  • acute renal failure
  • rash
  • urticaria
  • cutaneous vasculitis
  • severe and disabling arthralgia
  • vesicular bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • vitamin B12 deficiency
  • dyspnea
  • unstable angina
  • dizziness
  • decreased appetite
  • gastrointestinal disturbance
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air from entering, and it is best to keep it at a temperature between 1 degree and 30 degrees Celsius. This helps maintain the efficacy of the medication and prevent deterioration.

Appearance and packaging

Appearance

Red oval film-coated tablet

Package unit

30 tablets/box [(10 tablets/PTP) × 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.